
    
      A Phase 1, randomized, placebo-controlled, dose-escalation study to evaluate the safety and
      tolerability of ascending single subcutaneous and intravenous doses of MEDI4212 in subjects
      with immunoglobulin E (IgE) greater than or equal to (>=) 30 international units per
      milliliters (IU/mL).
    
  